Volume : 10, Issue : 09, September – 2023
Title:
11. INNOVATIVE APPROACHES FOR PULSATILE DRUG DELIVERY SYSTEM
Authors :
O.Girija kumari* ,J.N.Suresh Kumar,A.Venkata Seshu Krishna Rao,G.Venkata Anusha,Shaik Siddikh, S.Naga Sirisha and K. Ravichand
Abstract :
With the advancement of the technologies in the pharmaceutical field, drug delivery systems have drawn an increasing interest over the last few years. Nowadays, the importance of pharmaceutical galenic research is turned towards Chronopharmaceutical drug delivery systems (CDDS) as they deliver the drug at the right site of action at the right time and in the right amount based on circadian rhythms, thus providing spatial and temporal delivery and increasing patient compliance. Sustained and controlled drug delivery system release the drug at a substantially steady rate of release per unit of time. However, there are instances where maintaining a constant blood level of a drug is not desirable. In such cases a pulsatile drug delivery may be more advantageous. A pulse has to be designed in such a way that a complete and rapid drug release is achieved after the lag time. The aim of this current review is to describe, the diseases requiring CDDS, methodologies involved for the existing systems and more focus on the time induced and stimuli induced methodologies, recent update and CDDS product currently available in the market.
Keywords: Pulsatile, lag time, circadian rhythm, time induced, stimuli induced
Cite This Article:
Please cite this article in press O.Girija Kumari et al, Innovative Approaches For Pulsatile Drug Delivery System, Indo Am. J. P. Sci, 2023; 10 (09).
Number of Downloads : 10
References:
1. Chourasia MK, Jain SK. Chronopharmaceutics, Pulsatile drug delivery system as current trend. J. Pharm. Pharm. Sci, 2003;6:33-66.
2. Smolensky MH, Peppas NA. Chronobiology, drug delivery, and chronotherapeutics, Adv. Drug Del. Reviews 2007;59:828-851.
3. Rajkumar K, SainathGoud R, SuryasriLavanya A, Sangamesh T, Pandey D. Current techniques in pulsatile drug delivery: A review. Int Res J Pharm 2013:4(3):77-84
4. GohelM C, Sumitra M. G. Modulation of active pharmaceutical material release from a novel ‘tablet in capsule system’ containing an effervescent blend. J.Control. Release, 2002, 79: 157–164.
5. Patel JD, Aneja K, Majumdar SH. Pulsatile Drug Delivery System: An User Friendly Dosage Form. J.Control. Release, 2010;2(2):204-215.
6. Krogel I, Bodmeier R. Evaluation of an enzyme-containing capsular shaped pulsatile drug delivery system. Pharm Res 1999;16(9):1424-1429
7. Krogel I, Bodmeir R. Pulsatile drug release from an insoluble capsule body controlled by erodible plug. Pharm Res, 1998;15:474-81
8. Cai K, Luo Z, Hu Y. magnetically triggered reversible controlled drug delivery from micro fabricated polymeric multi reservoir devices. Adv. Mater, 2009;21:4045–4049
9. Kulkarni RV, Biswanath SA. Electroresponsive polyacrylamide-grafted-xanthan hydrogels for drug delivery. J. Bioactive Compatible Poly 2009;24:368- 384.
10. Qiu Y, Park K. Environment-sensitive hydrogels for drug delivery. Adv. Drug Del. Reviews 2001;53:321–339
11. Dey NS, Majumdar S, Rao MEB. Multiparticulate drug delivery systems for controlled release. Tropi. J. Pharm. Res, 2008;7(3):1067-1075.
12. Jessy S, Vishal P. Novel Floating Pulsatile Approach for Chronostherapeutic Release of Indomethacin. Dhaka Univ. J. Pharm. Sci 2007;6(1):37-41.
13. Youan BC, Chronopharmaceutics: gimmick or clinically relevant approach to drug delivery, J.Control. Rel, 2004; 98: 337–353.
14. AnilKumar S N, Kavitha K, Vinaykumar K.Development of chronopharmaceutical drug delivery system of trimetazidine hydrochloride for anginapectoris. Int.J.Drug Dev. & Res, 2010;2(2): 371-378.
15. Najmuddin M, Vishal Ashok Patel, Azgar Ali, Shelar S, Tousif K. Development and evaluation of pulsatile drug delivery system of flurbiprofen. Res J of Pharm Bio and Che Sci.2010; 1(2): 285- 90.
16. Mastiholimath VS, Dandagi PM, Jain SS, Gadad AP, Kulkarni AR. Time and pHdependent colon specific colon specific, pulsatile delivery of theophylline fornocturnal asthma. Int J pharm 2006;328:49-56.
17. Gohel MC, Manhapra SG. Modulation of active pharmaceutical material release from a novel ‘tablet in capsule system’ containing an effervescent blend. J ContRel. 2002;79:157-164.
18. Sandeep Singh, Marina Koland. Formulation and evaluation of pulsatile drug delivery systems of glipizide for the management of type-ii diabetes mellitus. Journal of Drug Delivery & Therapeutics. 2016; 6(1):11-18.
19. Gandhi BR, Mundada AS and Gandhi PP: Chronopharmaceutics: as a clinically relevant drug delivery system. Drug delivery 2011; 18(1); 1-18.
20. Kumar Amit and Ranga Sonam :Pulsatile Drug Delivery System :Method and Technology Review Int.J.Drug Dev& Res., 2012(4)4:95-107.
21. Janugade B.U.,PatilS.V.,Lade P.D.Formulation and evaluation of press coated monteluast sod.Tablets for pulsatile drug delivery system. Int J Chem Tech Res, 2009;1:690-691
22. Qureshi J., Mohd A., Ahuja A., Baboota S, Ali J. Chronomodulated drug delivery system of salbutamol sulphate for treatment of nocturnal Asthma. Indian J Pharm Sci, 2008; 70 (3): 351-356
23. Cutolo M., Straub R.H. Circadian rhythms in arthritis: Hormonal effects on the immune / inflammatory reaction. Autoimmun Rev, 2008; 7: 223-228
24. Roy P., Shahiwala A. Statistical optimization of ranitidine HCl floating pulsatile delivery system for chronotherapy of nocturnal acid breakthrough. Eur J Pharm Sci, 2009; 37: 363-369.
25. Levi F, Christian F, Abdoulaye K, De la Valette L, Focan- Henrard D, Baron B, Kreutz F, Giacchetti S. Implication of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv. Drug Delivery Rev ,2007;59:1015-1035.
26. Chancellor M, Oefelein M, Vasavada S. Obesity is associated with a more severe OAB disease state. Once daily trospium chloride XR is efficacious in the obese patient with the OAB syndrome. Neurourol.Urodynam.2010; 29:551–554.
27. Pani L. Marchese G, Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release, Expert Opinion on Drug Delivery, 2009; 6(3): 319–331, 2009.
28. Ezeugo, U. and Glasser, S. P. Clinical benefits versus shortcomings of diltiazem once-daily in the chronotherapy of cardiovascular diseases. Expert Opin Pharmacother, 2009; 10: 485-491.
29. Weisler R, Joyce M, McGill L, Lazarus A, Szamosi J, Eriksson H; Moonstone Study Group. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study.CNS Spectr. 2009; 14(6):299-313.
30. Schwartz SL, Wu JF, Berner B. Metformin extended release for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother. 2006;7(6):803-809.
31. Julian F. Guest, Dele Abegunde, Francis J. Ruiz. Cost Effectiveness of Controlled-Release Oxybutynin Compared with Immediate-Release Oxybutynin and Tolterodine in the Treatment of Overactive Bladder in the UK, France and Austria.Clinical Drug Investigation2004; 24 (6): 305-321.
32. Biederman, J, Quinn, D, Weiss, M et al, Efficacy and safety of Ritalin, LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder.Paediatr Drugs. 2003; 5:833–841.
33. André Herchuelz,, Fabienne Carreer-Bruhwyler, Jacques Crommen.Clinical pharmacokinetics of once-daily molsidomine From immediate-release to prolonged-release once-daily formulations. American Journal of Drug Delivery 2004; 2 (2): 131-141
34. Smith DH.Pharmacology of cardiovascular chronotherapeutic agents. Am 2001; 14(92):296-301.